What is SDIX?
SDIX operates as a key player in the biotechnology and diagnostics landscape, offering a comprehensive suite of products and services centered around GMP antibody production. Their offerings cater to critical markets including in vitro diagnostics (IVD), anatomic pathology, biotechnology, and pharmaceuticals. With a legacy spanning over three decades, SDIX is dedicated to advancing antibody-based solutions that facilitate both diagnostic advancements and commercialization objectives for its clientele. The company's expertise is crucial for clients requiring reliable and scalable antibody manufacturing.
How much funding has SDIX raised?
SDIX has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for SDIX?
The recent strategic investment signals a pivotal phase for SDIX, likely enabling accelerated development of its product pipeline and expansion of its manufacturing capabilities. As a company operating within the competitive IVD and biotechnology sectors, this capital infusion is expected to bolster its market presence and support ongoing innovation in antibody technology. SDIX's focus on GMP compliance and large-scale production positions it to capitalize on increasing demand for high-quality biological reagents in both research and clinical applications. Future growth will likely involve deepening partnerships and enhancing its service offerings to meet evolving industry needs.
See full SDIX company page
